[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Romanova et al., 2010 - Google Patents

Effect of antibodies to glutamate on retention of conditioned passive avoidance response in rats with ischemic injury of the prefrontal cortex

Romanova et al., 2010

Document ID
11031308885886395873
Author
Romanova G
Shakova F
Gorbatov V
Kvashennikova Y
Davydova T
Publication year
Publication venue
Bulletin of experimental biology and medicine

External Links

Snippet

Experiments were performed on rats with bilateral photothrombosis of vessels in the prefrontal cortex. Intranasal administration of antibodies to glutamate (1 h after ischemia of the brain cortex) improved retention of conditioned passive avoidance response, which was …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Similar Documents

Publication Publication Date Title
Reeth et al. Stimulated activity mediates phase shifts in the hamster circadian clock induced by dark pulses or benzodiazepines
Bieber et al. Human antibodies accelerate the rate of remyelination following lysolecithin‐induced demyelination in mice
Jansen et al. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss
Thotala et al. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells
Takahashi et al. Environmental enrichment enhances autophagy signaling in the rat hippocampus
Hosseini et al. The effect of treadmill running on passive avoidance learning in animal model of Alzheimer disease
MX2013000808A (en) A method of treating alzheimer's disease.
Wang et al. Protective effects of ACY-1215 against chemotherapy-related cognitive impairment and brain damage in mice
Wu et al. MST4 kinase inhibitor hesperadin attenuates autophagy and behavioral disorder via the MST4/AKT pathway in intracerebral hemorrhage mice
Chen et al. Antidepressant-like effect of 3-n-butylphthalide in rats exposed to chronic unpredictable mild stress: modulation of brain-derived neurotrophic factor level and mTOR activation in cortex
US5763492A (en) Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
Romanova et al. Effect of antibodies to glutamate on retention of conditioned passive avoidance response in rats with ischemic injury of the prefrontal cortex
Balducci et al. Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT 1A receptor antagonist WAY 100635
Reynolds Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia
JP2018516940A (en) Use of H3K9me3 regulation to improve cognitive function
CN111886005B (en) Use of fluoroethyl normemantine for the prevention and treatment of anxiety
ES2403558T3 (en) Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases
Chekman et al. Nootropics in comlex therapy of chronic cerebral ischemia
RU2557003C2 (en) Peptide having neuroprotective and nootropic activity and pharmaceutical composition based thereon
Jiang et al. Spaced training enhances contextual fear memory via activating hippocampal 5-HT2A receptors
Burkhardt One-trial backward fear conditioning in rats as a function of US intensity
Khastar et al. Cyanocobalamin improves memory impairment via inhibition of necrosis and apoptosis of hippocampal cell death after transient global ischemia/reperfusion
Petty et al. Intracortical glutamate injection produces helpless-like behavior in the rat
Liu et al. Icariside II affects hippocampal neuron axon regeneration and improves learning and memory in a chronic cerebral hypoperfusion rat model
Ma et al. 17AAG improves histological and functional outcomes in a rat CCI model through autophagy activation and apoptosis attenuation